You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Development of an irreversible covalent inhibitor of FMS-like tyrosine kinase receptor 3 for treating acute myeloid leukemia

    SBC: BRIDGENE BIOSCIENCES INC            Topic: 102

    PROJECT SUMMARY Acute myeloid leukemia (AML), a malignant disease of hematopoietic precursor cells in the bone marrow, is one of the most common cancers in adults accounting for 1% of all cancers. AML is typically diagnosed later in life with individuals 60 and older having a long-term survival rate of merely 5-15%. Cytogenic analysis of the abnormal cells at the time of diagnosis has proven to be ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  2. Chemical-based Nitric Oxide Gas-generating Drug Device for the Treatment of Pulmonary Hypertension

    SBC: Technology Commercialization Partners LLC            Topic: NHLBI

    ABSTRACT Pulmonary hypertension (PH) is a highly debilitating disease that affects about 1% of the global population, which increases up to 10% in individuals aged more than 65 years. The life expectancy for these patients is less than 10 years after diagnosis, and no specific drugs are available for pharmacologic treatment. Despite the introduction PDE5, prostacyclin analogs, and endothelin antag ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  3. Clinical feasibility of a non-invasive, low-cost wearable for measuring air trapping in COPD

    SBC: SAMAY, INC.            Topic: NHLBI

    ABSTRACTChronic Obstructive Pulmonary Disease (COPD) is the third leading cause of hospitalization in the US. Exacerbations - a worsening or “flare up” of symptoms - cause most COPD hospitalizations. Since most exacerbations can be treated with changes of inhalers and/or oral medications, at-home detection of lung function deterioration may facilitate earlier intervention and help delay or pre ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  4. Preventing liver fibrosis in alcoholic hepatitis by enhancing liver regenerative capacity via transient telomere extension using lipid nanoparticle-encapsulated TERT mRNA

    SBC: REJUVENATION TECHNOLOGIES INC            Topic: 400

    Abstract Rejuvenation Technologies Inc. (RTI) aims to prevent liver fibrosis in alcoholic hepatitis (AH) by enhancing liver regenerative capacity. AH is an acute form of alcoholic liver disease with mortality of up to 50% within 1 month of presentation. Most AH patients exhibit advanced fibrosis/cirrhosis, which contributes to acute-on-chronic liver failure. RTI will ameliorate/prevent this fibros ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  5. A novel role for Reelin therapeutics in inflammatory bowel disease

    SBC: REELIN THERAPEUTICS, INC.            Topic: 300

    Abstract Factors that contribute to the onset of inflammatory bowel disease (IBD) remain incompletely understood. Although specific genetic factors may increase risk, most IBD cannot be readily explained based on genetics. Dysbiosis in intestinal microbiomes also has been implicated. Once IBD is established, chronic inflammation is a central hallmark and also a major target for therapy. Both forms ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  6. FH-Fc as a Pre-Exposure Prophylactic for Tickborne Disease

    SBC: Planet Biotechnology Incorporated            Topic: NIAID

    Lyme disease (LD) is the most prevalent vector-borne disease in the United States, with up to 300,000 cases a year. LD is caused by several species of the spirochete bacteria Borrelia burgdorferi sensu lato (the Lyme borreliae), which are transmitted by ticks from animal (bird, rodent) reservoirs to human hosts. While a short course of antibiotics is usually effective in eliminating the bacteria a ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  7. A Vaccine for Acute Flaccid Myelitis

    SBC: ALEPH THERAPEUTICS INC            Topic: NIAID

    SUMMARYIn 2014 the United States experienced an outbreak of a previously unknown neurological disease with polio-like symptoms later known as acute flaccid myelitis (AFM). A biennial surge in cases of AFM in 2016 and 2018 has alarmed public health officials. Since then, rapidly accumulating clinical, immunological, and epidemiological evidence has pointed to EV-D68 as the major causative agent of ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  8. Develop and Commercialize the Bayesian Dose-Response Modeling System and Services

    SBC: KS & ASSOCIATES LLC            Topic: NIEHS

    PROJECT SUMMARY Chemical risk assessment is widely applied in industries and regulatory agencies as an important tool to evaluate chemical toxicity in support of chemical registration, safety evaluation, and exposure limitation development. One of the most notable improvements in dose-response assessment - a required quantitative step in risk assessment - is the development of benchmark dose (BMD) ...

    STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  9. Wireless withdrawal detection and monitoring system for neonatal abstinence syndrome.

    SBC: REKOVAR INC            Topic: NIDA

    PROJECT SUMMARY Neonatal abstinence syndrome (NAS) is an opioid withdrawal syndrome that develops shortly after birth to in utero-exposed neonates. The cost of NAS is high: newborns with NAS are typically receive care in the Neonatal Intensive Care Unit (NICU), where the daily cost of care is high. Nearly 22,000 infants are born with NAS each year at a cost of $1.5 billion1. Moreover, medication-b ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  10. Prevention of White Matter Injury in Premature Infants

    SBC: Medosome Biotec, LLC            Topic: NICHD

    ABSTRACTUp to 30% of low birth weight preterm infants manifest some form of periventricular white matter injury (PWMI) making it the most common form of brain injury affecting premature infants. PWMI is associated with significant morbidity, as affected individuals may have profound intellectual impairment and cerebral palsy. Highlighting the magnitude of PWMI, each year more than 400,000 infants ...

    STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government